

Singapore Exchange Limited

Thank you volatility

SINGAPORE | FINANCE | 3Q18 RESULTS

Highlights

- 3Q18 PATMI beat our estimates by 11%. Revenue of S\$222mn is the highest since listing. It was securities revenue that exceeded our expectations.
- Derivatives business drove revenue growth with volumes surging by 34% YoY. FX derivatives enjoyed a stellar 89% spike in volumes.
- SGX will launch new Indian equity derivative products by June18, linked to a so-called "publicly available reference price".
- Maintain BUY. Our target price raised to \$\$9.20 (previously \$\$8.89), in-line with the increase in our FY18e earnings by 4%.

Results at a glance

(SGD mn)	3Q18	3Q17	YoY	2Q18	QoQ	Comments
						SDAV rose 17% YoY to S\$1.45bn but
Securities	61.7	55.3	12%	51.8	19%	average equity clearing fee came off
						2% to 2.87bps in 3Q18.
						Derivatives volumes surged 34% YoY,
Derivatives	90.5	75.2	20%	83.3	9%	but offset against 11% decline in
						contract fees to S\$1.07.
Others	70.0	72.2	-3%	69.9	0%	As expected, post trade services
						revenue declined 11% YoY.
Total Revenue	222.2	202.7	10%	205.0	8%	
Opex	(104.4)	(99.7)	5%	(102.1)	2%	Operating expenses was contained to
Орск	(104.4)	(33.7)	370	(102.1)	270	capture operating leverage.
Net Income	100.5	83.1	21%	88.4	14%	
DPS	5.0	5.0	0%	5.0	0%	

Source: Company, PSR

The Positives

- + Derivatives the growth driver. Derivatives revenue rose 20% YoY stemming from the 34% surge in volumes. However, average fee per contract was down 11% YoY to \$\$1.07 due to change in product mix. Improvement in volumes came largely from China A50, Nikkei 225 and FX futures products.
- **+ Operating leverage intact.** Revenue rose close to S\$17mn QoQ and almost 70% (or S\$12mn) flowed to net profits. SGX has managed to keep operating expenses relatively stable despite the improvement in revenue.
- + Higher number of listing expected. SGX mentioned FY18 equity listings would likely exceed FY17. This implies at least another 5 more IPOs in 4QFY18. Funds raised are up 6-fold YTD.

The Negatives

- **No resolution with Indian exchanges.** Recall that in Feb18, Indian exchanges announced they would stop licensing their index or provide data to foreign exchanges. This was to affect the continuity of SGX Nifty Fifty products. SGX recently stated it would list new India equity derivative products in June18. Unclear to us how these new products will be "seamlessly traded" and accepted by market participants. Also, there is the worry if such product could elicit some response from the Indian exchanges.

Investment Actions

We maintain our BUY recommendation. The return of volatility, continuous stream of new products and operating leverage will be supportive of earnings growth. Valuations are attractive in view of the 35% ROEs, 4% dividend yield and momentum in earnings.



23 April 2018

BUY (Maintain)

TOTAL RETURN	25.9%
TARGET PRICE	SGD 9.20
FORECAST DIV	SGD 0.32
LAST DONE PRICE	SGD 7.56

COMPANY DATA

BLOOMBERGTICKER	SGX SP
O/S SHARES (MN):	1,070
MARKET CAP (USD mn / SGD mn):	6141/8089
52 - WK HI/LO (SGD):	8.5 / 7.1
3M Average Daily T/O (mn):	3.01

MAJOR SHAREHOLDERS (%)

SEL	Holdings Pte Ltd	23.34%

PRICE PERFORMANCE (%)

	1M T H	3 M T H	1Y R
COMPANY	0.9	(4.7)	5.3
STIRETURN	1.90	1.00	17.50

PRICE VS. STI



Source: Bloomberg, PSR

KEY FINANCIALS

Y/E June	FY16	FY 17	FY 18 e	FY 19 e
Revenue (SGD mn)	818	801	852	896
EBITDA (SGD mn)	469	460	498	513
NPAT (SGD mn)	349	340	377	396
EPS (Cents)	32.6	31.8	35.2	37.0
PER, (X)	22.2	23.8	20.9	19.9
P/BV, (X)	7.9	8.2	7.6	7.1
DPS (Cents)	28.0	28.0	32.0	32.0
Div Yield, (%)	4%	4%	4%	4%
ROE, (%)	36%	34%	35%	35%

Source: Bloomberg, Company, PSR

Valuation Method: DCF

(WACC: 7.35%, Terminal Growth Rate: 1.1%)

Phillip Research Team (+65 6212 1850)

research@phillip.com.sg

Page | 1 | PHILLIP SECURITIES RESEARCH (SINGAPORE) MCI (P) 074/10/2017

Ref. No.: SG2018_0090



Financials

Income Statement					
Y/E Jun, SGD mn	FY15	FY16	FY17	FY18e	FY19e
Securities	209	205	205	214	198
Derivatives	296	325	303	350	403
Others	238	288	293	287	295
Operating revenue	742	818	801	852	896
Operating expenses	377	409	399	411	431
Operating profit	402	409	402	441	465
Other gains/(losses)	8	6	6	10	10
Associates & JVs	2	1	1	1	2
Profit Before Tax	412	416	409	453	476
Taxation	-63	(67)	(69)	(75)	(80)
Net Income, reported	349	349	340	377	396

349

349

340

377

396

Shareholder Equity

Balance Sheet					
Y/E Jun, SGD mn	FY15	FY16	FY17	FY18e	FY19e
ASSETS					_
PPE	61	62	80	66	64
Others	237	245	348	359	364
Total non-current assets	298	307	429	424	429
Accounts receivables	654	930	815	857	875
Cash	790	806	736	768	817
Securities clearing funds	60	60	60	60	60
Others	0	3	1	1	1
Total current assets	1,504	1,799	1,613	1,686	1,753
Total Assets	1,802	2,105	2,041	2,110	2,182
LIABILITIES					
Accounts payables	718	1,013	892	856	874
Short term loans	0	0	0	0	0
Others	86	85	82	87	87
Total current liabilities	805	1,098	973	943	961
Long term loans	0	0	0	0	0
Others	21	18	35	35	35
Total non-current liabilities	21	18	35	35	35
Total Liabilities	825	1,116	1,009	978	996
EQUITY					
Non-controlling interests	0	0	0	0	0

976

990

1,033

1,112

1,164

Per s	share	data	(SGD	Cents)

Net Income, adj.

Y/E Jun	FY15	FY16	FY17	FY18e	FY19e
EPS, reported	32.59	32.6	31.8	35.2	37.0
DPS	28.00	28.0	28.0	32.0	32.0
BVPS	86.20	91.2	92.5	96.5	103.9

Cash Flow						Valuation Ra
Y/E Jun, SGD mn	FY15	FY16	FY17	FY18e	FY19e	Y/E Jun
CFO						P/E (X), adj.
Profit before tax and Assoc.&JV	410	415	407	451	475	P/B (X)
Depreciation & Amortisation	57	60	58	57	49	EV/EBITDA
WC changes	14	17	(21)	(42)	7	Dividend Yi
Others	11	2	3	1	(1)	Growth & M
Cash generated from ops	493	494	447	467	530	Growth
Taxpaid	(64)	(70)	(67)	(75)	(80)	Revenue
Cashflow from ops	429	423	380	392	450	EBITDA
CFI						EBIT
CAPEX, net	(82)	(74)	(60)	(71)	(67)	Net profit,
Others	(13)	11	(87)	13	10	Margins
Cashflow from investments	(95)	(63)	(147)	(58)	(57)	EBITDA ma
CFF						EBIT margir
Loans, net of repayments	0	0	0	0	0	Net profit n

(332)

(13)

(345)

15

(300)

(308)

(76)

(9)

(300)

(308)

26

790

(8)

Valuation Ratios					
Y/E Jun	FY15	FY16	FY17	FY18e	FY19e
P/E (X), adj.	24.0	22.2	23.8	20.9	19.9
P/B (X)	9.1	7.9	8.2	7.6	7.1
EV/EBITDA (X), adj.	10.5	8.8	9.4	8.7	8.4
Dividend Yield (%)	3.6%	3.9%	3.7%	4.3%	4.3%
Growth & Margins (%)					
Growth					
Revenue	13.9%	10.2%	-2.1%	6.4%	5.1%
EBITDA	41.6%	10.0%	-6.8%	15.6%	4.8%
EBIT	13.9%	10.2%	-2.1%	6.4%	5.4%
Net profit, adj.	22.3%	0.0%	-2.7%	11.1%	5.0%
Margins					
EBITDA margin	61.9%	57.3%	57.4%	58.4%	57.3%
EBIT margin	54.2%	50.0%	50.2%	51.8%	51.9%
Net profit margin	47.0%	42.7%	42.4%	44.3%	44.3%
Key Ratios					
ROE (%)	36.8%	35.5%	33.6%	35.2%	34.8%
ROA (%)	20.3%	17.9%	16.4%	18.2%	18.5%
Net Gearing (X)	Net Cash I	Net Cash	Net Cash	Net Cash	Net Cash

Source: Company, PSR

Net change in cash

Cashflow from financing

Dividends

Others

CCE, end

(300)

(300)

34

768

0

(343)

(343)

50

817

0

^{*}Forward multiples & yields based on current market price; historical multiples & yields based on historical market price.





PSR Rating Syste	m		
Total Returns	Recommendation	Rating	
> +20%	Buy	1	
+5% to +20%	Accumulate	2	
-5% to +5%	Neutral	3	
-5% to -20%	Reduce	4	
<-20%	Sell	5	

Remarks

We do not base our recommendations entirely on the above quantitative return bands. We consider qualitative factors like (but not limited to) a stock's risk reward profile, market sentiment, recent rate of share price appreciation, presence or absence of stock price catalysts, and speculative undertones surrounding the stock, before making our final recommendation



SINGAPORE EXCHANGE LIMITED RESULTS

Head of Research

Paul Chew - paulchewkl@phillip.com.sg

Contact Information (Singapore Research Team)
Research Associate

Alvin Chia - alvinchiawy@phillip.com.sg

Chen Guangzhi - chengz@phillip.com.sg

Research Operations Officer

Mohamed Amiruddin - amiruddin@phillip.com.sg

Consumer | Healthcare

Soh Lin Sin - sohls@phillip.com.sg

Transport | REITs (Industrial)

Richard Leow, CFTe, FRM - richardleowwt@phillip.com.sg

REITs (Commercial, Retail, Healthcare) | Property

Tara Wong - tarawongsj@phillip.com.sg

Oil & Gas | Energy

REITs (Commercial, Retail, Healthcare) | Property

Dehong Tan - tandh@phillip.com.sg

Technical Analysis

Macro

Jeremy Ng - jeremyngch@phillip.com.sg

Pei Sai Teng - peist@phillip.com.sg

US Equity

Ho Kang Wei - hokw@phillip.com.sg

SINGAPORE

Phillip Securities Pte Ltd

Raffles City Tower 250, North Bridge Road #06-00 Singapore 179101

Tel +65 6533 6001 Fax +65 6535 6631

Website: www.poems.com.sg

JAPAN

Phillip Securities Japan, Ltd.

4-2 Nihonbashi Kabuto-cho Chuo-ku, Tokyo 103-0026 Tel +81-3 3666 2101

> Fax +81-3 3666 6090 Website: www.phillip.co.jp

> > THAILAND

Phillip Securities (Thailand) Public Co. Ltd

15th Floor, Vorawat Building, 849 Silom Road, Silom, Bangrak, Bangkok 10500 Thailand Tel +66-2 6351700 / 22680999 Fax +66-2 22680921

Website www.phillip.co.th

UNITED STATES
Phillip Capital Inc

141 W Jackson Blvd Ste 3050 The Chicago Board of Trade Building Chicago, IL 60604 USA Tel +1-312 356 9000

Fax +1-312 356 9005 Website: www.phillipusa.com

INDIA

PhillipCapital (India) Private Limited

No.1, 18th Floor, Urmi Estate 95, Ganpatrao Kadam Marg Lower Parel West, Mumbai 400-013 Maharashtra, India Tel: +91-22-2300 2999 / Fax: +91-22-2300 2969

Website: www.phillipcapital.in

website: www.pnillipcapital.in

CAMBODIA

Phillip Bank Plc

Ground Floor of B-Office Centre,#61-64, Norodom Blvd Corner Street 306,Sangkat Boeung Keng Kang 1, Khan Chamkamorn, Phnom Penh, Cambodia Tel: 855 (0) 7796 6151/855 (0) 1620 0769

Website: www.phillipbank.com.kh

Contact Information (Regional Member Companies)

MALAYSIA

Phillip Capital Management Sdn Bhd

B-3-6 Block B Level 3 Megan Avenue II, No. 12, Jalan Yap Kwan Seng, 50450 Kuala Lumpur

> Tel +603 2162 8841 Fax +603 2166 5099

Website: www.poems.com.my

INDONESIA

PT Phillip Securities Indonesia

ANZ Tower Level 23B, JI Jend Sudirman Kav 33A Jakarta 10220 – Indonesia Tel +62-21 5790 0800 Fax +62-21 5790 0809

Website: www.phillip.co.id

FRANCE

King & Shaxson Capital Limited

3rd Floor, 35 Rue de la Bienfaisance 75008 Paris France

> Tel +33-1 45633100 Fax +33-1 45636017

Website: www.kingandshaxson.com

AUSTRALIA

Phillip Capital Limited

Level 10, 330 Collins Street Melbourne, Victoria 3000, Australia Tel +61-03 9629 8288 Fax +61-03 9629 8882

Website: www.phillipcapital.com.au

TURKEY

PhillipCapital Menkul Degerler

Dr. Cemil Bengü Cad. Hak Is Merkezi No. 2 Kat. 6A Caglayan 34403 Istanbul, Turkey Tel: 0212 296 84 84 Fax: 0212 233 69 29

Website: www.phillipcapital.com.tr

HONG KONG

Phillip Securities (HK) Ltd

11/F United Centre 95 Queensway Hong Kong

Tel +852 2277 6600 Fax +852 2868 5307 Websites: www.phillip.com.hk

CHINA

Phillip Financial Advisory (Shanghai) Co Ltd

No 550 Yan An East Road, Ocean Tower Unit 2318, Postal code 200001 Tel +86-21 5169 9200 Fax +86-21 6351 2940

Website: www.phillip.com.cn

UNITED KINGDOM

King & Shaxson Capital Limited

6th Floor, Candlewick House, 120 Cannon Street, London, EC4N 6AS Tel +44-20 7426 5950

Fax +44-20 7626 1757

Website: www.kingandshaxson.com

SRI LANKA

Asha Phillip Securities Limited

2nd Floor, Lakshmans Building, No. 321, Galle Road, Colombo 03, Sri Lanka Tel: (94) 11 2429 100 Fax: (94) 11 2429 199 Website: www.ashaphillip.net

DUBAI

Phillip Futures DMCC

Member of the Dubai Gold and Commodities Exchange (DGCX) Unit No 601, Plot No 58, White Crown Bldg, Sheikh Zayed Road, P.O.Box 212291 Dubai-UAE

Tel: +971-4-3325052 / Fax: + 971-4-3328895

SINGAPORE EXCHANGE LIMITED RESULTS



Important Information

This report is prepared and/or distributed by Phillip Securities Research Pte Ltd ("Phillip Securities Research"), which is a holder of a financial adviser's license under the Financial Advisers Act, Chapter 110 in Singapore.

By receiving or reading this report, you agree to be bound by the terms and limitations set out below. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.

The information and any analysis, forecasts, projections, expectations and opinions (collectively, the "Research") contained in this report has been obtained from public sources which Phillip Securities Research believes to be reliable. However, Phillip Securities Research does not make any representation or warranty, express or implied that such information or Research is accurate, complete or appropriate or should be relied upon as such. Any such information or Research contained in this report is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith.

Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this report are as of the date indicated and are subject to change at any time without prior notice. Past performance of any product referred to in this report is not indicative of future results.

This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This report should not be relied upon exclusively or as authoritative, without further being subject to the recipient's own independent verification and exercise of judgment. The fact that this report has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this report is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this report involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.

Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this report should take into account existing public information, including any registered prospectus in respect of such product.

Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this report, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this report.

Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.

To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold an interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this report. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this report.

The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.

This report is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this report may not be suitable for all investors and a person receiving or reading this report should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.

This report is not intended for distribution, publication to or use by any person in any jurisdiction outside of Singapore or any other jurisdiction as Phillip Securities Research may determine in its absolute discretion.

IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSES

Where the report contains research analyses or reports from a foreign research house, please note:

- (i) recipients of the analyses or reports are to contact Phillip Securities Research (and not the relevant foreign research house) in Singapore at 250 North Bridge Road, #06-00 Raffles City Tower, Singapore 179101, telephone number +65 6533 6001, in respect of any matters arising from, or in connection with, the analyses or reports; and
- (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, Phillip Securities Research accepts legal responsibility for the contents of the analyses or reports.